Effectiveness of Medilac-S as an Adjuvant to Conventional Irritable Bowel Syndrome Treatments: A Systematic Review with Meta-Analysis
Numerous clinical studies published in the Chinese language support the use of Medilac-S (<i>Bacillus subtilis</i> R0179 and <i>Enterococcus faecium</i> R0026; non-commercial name IBacilluS+) as an adjuvant in various indications, including ulcerative colitis, irritable bowel...
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artikel |
| Taal: | English |
| Gepubliceerd in: |
MDPI AG
2023-10-01
|
| Reeks: | Gastroenterology Insights |
| Onderwerpen: | |
| Online toegang: | https://www.mdpi.com/2036-7422/14/4/36 |